Roche Toradol patent to expire in May 1997 under federal appellate ruling.
Executive Summary
ROCHE TORADOL PATENT EXPIRES IN MAY 1997 UNDER APPEALS COURT RULING that will not allow Roche to add Waxman/Hatch time to the 20-year from filing patent term allowed by the General Agreement on Tariffs & Trade. Roche had claimed an expiration date of July 1998 in the case before the D.C. federal appeals court. Sales of the non-narcotic analgesic were $81.1 mil. from February to April 1994, the last reported quarter before Syntex was acquired by Roche.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth